Short introduction and history

Advances in Experimental Medicine and Biology

Volumn 678, Issue , 2010, Pages 1-10

  Raffa, Robert B ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; THIOTEPA;

ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHEMO FOG; COGNITION; COGNITIVE DEFECT; DEPRESSION; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG PENETRATION; DRUG STRUCTURE; DRUG TRANSPORT; HUMAN; LEARNING DISORDER; MEMORY DISORDER; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SURVIVAL TIME; ARTICLE; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG THERAPY; HISTORY; NEOPLASM;

ANTINEOPLASTIC AGENTS; COGNITION DISORDERS; DRUG THERAPY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEOPLASMS;

EID: 77956643799     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-6306-2_1     Document Type: Review

References (55)

1. Silberfarb PM, Philibert D, Levine PM. Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. Amer J Psychiatry 1980; 137:597-601. (Pubitemid 10107447)
2. Packer RJ, Meadows AT, Rorke LB et al. Long-term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 1987; 15:241-253. (Pubitemid 18015658)
3. Copeland DR, Dowell RE Jr, Fletcher JM et al. Neuropsychological effects of childhood cancer treatment. J Child Neurol 1988; 3:53-62. (Pubitemid 18044782)
4. Kramer J, Moore IM. Late effects of cancer therapy on the central nervous system. Seminars Oncol Nursing 1989; 5:22-28.
5. Meyers CA, Scheibel RS. Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology (Williston Park) 1990; 4:115-122. (Pubitemid 20251543)
6. Gamis AS, Nesbit ME. Neuropsychologic (cognitive) disabilities in long-term survivors of childhood cancer. Pediatrician 1991; 18:11-19. (Pubitemid 20335007)
7. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90:210-218. (Pubitemid 28114539)
8. Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? J Natl Cancer Instit 1998; 90:182-183. (Pubitemid 28114536)
9. Raffa RB, Duong PV, Finney J et al. Is 'chemo-fog'/chemo brain caused by cancer chemotherapy? J Clin Pharm Ther 2006; 31:129-138.
10. Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology 2001; 15:613-618. (Pubitemid 33739126)
11. Anderson-Hanley C, Sherman ML, Riggs R et al. Neuropsychological effect of treatments for adults with cancer: A meta-analysis and review of the literature. J Intl Neuropsychol Soc 2003; 9:967-982. (Pubitemid 37428441)
12. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions. J Natl Cancer Inst 2003; 95:190-197. (Pubitemid 36240631)
13. Tannock IF, Tim AA, Ganz PA et al. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004; 22:2233-2239. (Pubitemid 41095159)
14. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncol 1995; 4:61-66. (Pubitemid 26093776)
15. Schagen S, van Dam F, Muller M et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85:640-650. (Pubitemid 29075285)
16. Schagen SB, Muller MJ, Boogerd W et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Annals Oncol 2002; 13:1387-1397.
17. Brezden C, Phillips K, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18:2695-2701. (Pubitemid 30463551)
18. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485-493. (Pubitemid 34072533)
19. O'Shaughnessy JA. Effects of epoetin alfa on cognitive function, mood, asthenia and quality of life in women with breast cancer undergoing adjuvant chemotherapy. Clin Breast Cancer 2002; 3
20. Tchen N, Juffs HG, Downie FP et al. Cognitive changes, fatigue and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer: a prospective matched cohort study. J Clin Oncol 2003; 21:4175-4183. (Pubitemid 46606186)
21. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 2004; 100:2292-2299. (Pubitemid 38657875)
22. Meyers C. Neurocognitive dysfunction in cancer patients. Oncology 2000; 14:75-81.
23. Schagen SB, Hamburger HL, Muller MJ et al. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 2001; 51:159-165. (Pubitemid 32435496)
24. Kingma A, van Dommelen RI, Mooyaart EL et al. Slight cognitive impairment and magnetic resonance imaging abnormalities but normal school levels in children treated for acute lymphoblastic leukemia with chemotherapy only. J Pediatrics 2001; 139:413-420. (Pubitemid 32889519)
25. Kibiger G, Kirsh KL, Wall JR et al. My mind is as clear as it used to be: a pilot study illustrating the difficulties of employing a single-item subjective screen to detect cognitive impairment in outpatients with cancer. J Pain Symp Manage 2003; 26:705-715. (Pubitemid 36952346)
26. Appleton RE, Farrell K, Zaide J et al. Decline in head growth and cognitive impairment in survivors of acute lymphoblastic leukemia. Arch Disease Childhood 1990; 65:530-534. (Pubitemid 20151088)
27. Van Oosterhout AG, Ganzevles PG, Wilmink JT et al. Sequelae in long-term survivors of small cell lung cancer. Internatl J Rad Oncol Biol Phys 1996; 34:1037-1044. (Pubitemid 26105441)
28. Ahles TA. Do systemic cancer treatments affect cognitive function? Lancet Oncol 2004; 5:270-271. (Pubitemid 38541577)
29. Riva D, Giorgi C, Nichelli F et al. Intrathecal methotrexate affects cognitive function in children with medulloblastoma. Neurology 2002; 59:48-53. (Pubitemid 34742793)
30. Brown RT, Madan-Swain A, Walco GA et al. Cognitive and academic late effects among children previously treated for acute lymphocytic leukemia receiving chemotherapy as CNS prophylaxis. J Ped Psychia 1998; 23:333-340. (Pubitemid 28432425)
31. Shilling V, Jenkins V, Fallowfield L et al. The effects of hormone therapy on cognition in breast cancer. J Steroid Biochem Molec Biol 2003; 86:405-412. (Pubitemid 37412579)
32. Almeida OP, Flicker L. The mind of a failing heart: a systematic review of the association between congestive heart failure and cognitive functioning. Internal Med J 2001; 31:290-295. (Pubitemid 32734932)
33. Allena KV, Frier BM, Strachan MWJ. The relationship between type 2 diabetes and cognitive dysfunction: longitudinal studies and their methodological limitations. Eur J Pharmacol 2004; 490:169-175. (Pubitemid 38482170)
34. Liesker JJ, Postma DS, Beukema RJ et al. Cognitive performance in patients with COPD. Resp Med 2004; 98:351-356. (Pubitemid 38443695)
35. Antonelli Incalzi R, Marra C, Giordano A et al. Cognitive impairment in chronic obstructive pulmonary disease A neuropsychological and SPECT study. J Neurol 2003; 250:325-332. (Pubitemid 36399273)
36. Wilson RS, Mendes de Leon CF, Bennett DA et al. Depressive symptoms and cognitive decline in a community population of older persons. J Neurol Neurosurg Psychia 2004; 75:12126-12129.
37. Cimprich B, Ronis DL. Attention and symptom distress in women with and without breast cancer. Nursing Res 2001; 50:86-94. (Pubitemid 33603795)
38. Wefel S, Lenzi R, Theriault R et al. 'Chemobrain' in breast carcinoma? A prologue. Cancer 2004; 101:466-475.
39. Hannay HJ, Levin HS. Selective reminding test: an examination of the equivalence of four forms. J Clin Exper Neuropsychol 1985; 7:251-263.
40. Holland J. New treatment modalities in radiation therapy. J Intravenous Nursing 2001; 24:95-101. (Pubitemid 32230267)
41. Noad R, Narayanan KR, Howlett T et al. Evaluation of effects of radiotherapy for pituitary tumors on cognitive function and quality of life. Clin Oncol Royal College Radiol 2004; 16:233-237. (Pubitemid 38696962)
42. Keime-Guibert F, Napolitano M, Delattre J. Neurological complications of radiotherapy and chemotherapy. J Neurol 1998; 245:695-708. (Pubitemid 28468468)
43. Bonadonna G, Brusamolino E, Valagussa P. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Eng J Med 1976; 294:405-410.
44. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-positive breast cancer: the results of 20 years follow-up. N Eng J Med 1995; 332:901-906.
45. Harris J. Morrow M, Norton L. Cancer of the breast. In: DeVita VT, Hellman S, Rosenberg SA. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven Publishers, 1997; 2:1541-1616.
46. Kemper E, Boogerd W, Thuis I et al. Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours? Cancer Treat Rev 2004; 30:415-423. (Pubitemid 38968122)
47. Neuwelt EA, Barnett P, Barranger J et al. Inability of dimethyl sulfoxide and 5-fluorouracil to open the blood-brain barrier. Neurosurgery 1983; 12:29-34. (Pubitemid 13181854)
48. MacDonell LA, Potter PE, Leslie RA. Localized changes in blood-brain barrier permeability following the administration of antineoplastic drugs. Cancer Res 1978; 38:2930-2934. (Pubitemid 9001394)
49. Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases. Onkologie 2002; 25:474-479. (Pubitemid 36160188)
50. Neuwelt EA, Barnett PA, Frenkel EP. Chemotherapeutic agent permeability to normal brain and delivery to avian sarcoma virus-induced brain tumors in the rodent: observations on problems of drug delivery. Neurosurgery 1984; 14:154-160. (Pubitemid 14198777)
51. Fliessbach K, Urbach H, Helmstaedter C et al. Cognitive performance and magnetic resonance imaging findings after high-dose systemic and intraventricular chemotherapy for primary central nervous System lymphoma. Arch Neurol 2003; 60:563-568. (Pubitemid 36427970)
52. Caine GJ, Stonelake PS, Rea D et al. Coagulopathic complications in breast cancer. Cancer 2003; 98:1578-1586. (Pubitemid 37238612)
53. Love S. Chemobrain/Cognitive Dysfunction. The Website for Women. http://www.susanlovemd.org/faq/ chemobrain/chemobrain.htmll
54. Foreman J. "Chemo Brain" Leaves Patients at a Loss. Health Sense Columns 2003, http://www.myhealthsense. com/F030701-Chemo.html
55. Madhyastha S, Somayaji SN, Rao MS et al. Hippocampal brain amines in methotrexate-induced learning and memory deficit. Canad J Physiol Pharmacol 2002; 80:1076-1084. (Pubitemid 36002665)